The GI Monitor Advisory Committee consists of qualified researchers, physicians and patients, all of whom have a collective interest in making progress towards the best possible treatments for Crohn’s and Ulcerative Colitis. Each member contributes his/her opinion to guide the GI Monitor Product Development Roadmap and ensure that the service represents the needs of IBD patients, physicians and researchers.

If you are interested in becoming a committee member, please contact us


Robert H. Pittman, M.D.

Board Certified Gastroenterologist

Dr. Pittman is a graduate of Brown University and New York University School of Medicine. He completed his Internal Medicine Internship, Residency, Chief Residency and Clinical Fellowship in Gastroenterology at The Mount Sinai Medical Center where he also received advanced training and expertise in the techniques of gallstone removal, bile duct evaluation and video capsule endoscopy.

Dr. Pittman has a special interest in inflammatory bowel disease, gastrointestinal malignancy and therapeutic GI endoscopy. He is a member of several medical associations, including the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy. Dr. Pittman is Board Certified in Internal Medicine and Board Certified in Gastroenterology.

Arun Swaminath

Arun Swaminath, M.D.

Columbia Presbyterian Medical Center

Dr. Swaminath is a leading clinical scientist at Columbia Presbyterian Medical Center in New York City. Presbyterian Hospital has been ranked in the top 10 hospitals in the country by US News & World Report.

Dr. Swaminath completed his Advanced Fellowship training in Inflammatory Bowel Disease as the Present-Levison Inflammatory Bowel Disease Fellow at Mt. Sinai Medical Center. Dr. Swaminath was involved in the development of several new clinical trails, management of IBD patients on cutting edge research therapies/protocols, and translational research involving mechanisms of action of drugs. A key accomplishment was his demonstration of the efficacy of Infliximab for treatment of Crohn’s strictures of the colon (Inflammatory Bowel Diseases 2007; 14:213-216). He has also developed expertise in the use of capsule endoscopy for investigation of small bowel disease, the use of emerging biologic therapies for the management of inflammatory bowel disease, and an interest in how the internet influences the behavior of patients with IBD.

A native of California, Dr. Swaminath completed his training, undergraduate through fellowship, at the University of California-San Diego, including spending an additional year as Chief Resident in Internal Medicine. Board Certified in Internal Medicine and Gastroenterology, Dr. Swaminath is currently working to build an Inflammatory Bowel Disease Center at Columbia University Medical Center. Organized around a multidisciplinary team of surgeons, pathologists, nutritionists, mental health professionals, and radiologists. The IBD Center will treat patients with inflammatory bowel disease in a multidisciplinary fashion as well as develop a data base of IBD patients, a tissue and serum bank, and perform clinical trials and collaborations for translational projects.


Stefanie Nowikow

IBD Patient

Stefanie Nowikow was diagnosed with IBD in March of 2008. Like many other IBD patients, she has received a diagnosis of both Crohn’s and Ulcerative Colitis since she began having symptoms in November of 2007. And like most of us, her top priority is to manage her symptoms and quality of life, regardless of the diagnosis. A graduate of the University of Missouri - St. Louis with a Bachelors of Science in Criminology and Criminal Justice, Stefanie has a passion for the outdoors. She refuses to let her IBD symptoms interfere with her love for boats, jet skis and motorcycles. She is currently training for a half-marathon! This type of passion makes Stefanie a perfect patient representative for the GI Monitor Advisory Committee. Her input will ensure that GI Monitor is helping patients and their physicians accurately track symptoms so that the best possible treatments can be applied and patients can continue to pursue their passions.